Compare AstraZeneca plc (AZN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Workiva Inc — how do they compare? AstraZeneca plc trades at $168.36 (market cap $253.13B), while Workiva Inc trades at $54.51 (market cap $3.01B). The key difference: AstraZeneca plc is far larger — about 84.1× Workiva Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| AZN | WK | |
|---|---|---|
Market Cap | $253.13B | $3.01B |
Sector | Health | Technology |
52-Week High | $209.48 | $93.31 |
52-Week Low | $137.44 | $44.31 |
Enterprise Value | $279.37B | $2.94B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Workiva (WK) trades at $54.54, up 4.54% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.77 exceeding expectations. Revenue growth remains solid at $884.57 million for 2025, projected to reach $926 million in 2026. Technical indicators show bullish moving averages while RSI levels suggest potential overbought conditions near-term.
Workiva presents a compelling growth story with 88.9% analyst buy ratings and a $71 consensus price target offering 30% upside. However, elevated valuation multiples (P/E 223.71, EV/EBITDA 71.73) and thin net margins (1.53%) warrant caution. Key risks include competitive pressures in compliance software and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
